

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 10875044-00011 Date of last issue: 04.02.2025
Date of first issue: 20.10.2022

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Ivermectin (0.50%) Liquid Formulation
Other means of identification : COOPERS PARAMAX POUR-ON FOR BEEF AND DAIRY CATTLE (50558)

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Veterinary product
Recommended restrictions on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Kilsheelan
Clonmel Tipperary, IE
Telephone : 353-51-601000
E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2	H319: Causes serious eye irritation.
Skin sensitisation, Category 1	H317: May cause an allergic skin reaction.
Germ cell mutagenicity, Category 2	H341: Suspected of causing genetic defects.
Specific target organ toxicity - single exposure, Category 3	H336: May cause drowsiness or dizziness.
Short-term (acute) aquatic hazard, Category 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0

Revision Date: 14.04.2025

SDS Number: 10875044-00011

Date of last issue: 04.02.2025
Date of first issue: 20.10.2022

Hazard pictograms



Signal word

: Warning

Hazard statements

: H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
H336 May cause drowsiness or dizziness.
H341 Suspected of causing genetic defects.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

: **Prevention:**

P201 Obtain special instructions before use.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Hazardous components which must be listed on the label:

Propan-2-ol

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
---------------	---------	----------------	---------------

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version
6.0

Revision Date:
14.04.2025

SDS Number:
10875044-00011

Date of last issue: 04.02.2025
Date of first issue: 20.10.2022

	EC-No. Index-No. Registration number		(% w/w)
Propan-2-ol	67-63-0 200-661-7 603-117-00-0	Flam. Liq. 2; H225 Eye Irrit. 2; H319 STOT SE 3; H336	>= 70 - < 90
7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate	2386-87-0 219-207-4 607-773-00-9	Skin Sens. 1; H317 Muta. 2; H341 STOT RE 2; H373 (nasal cavity) Aquatic Chronic 3; H412	>= 1 - < 2,5
Ivermectin	70288-86-7 274-536-0	Acute Tox. 2; H300 Acute Tox. 3; H311 STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10.000 M-Factor (Chronic aquatic toxicity): 10.000	>= 0,25 - < 1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause an allergic skin reaction.
Causes serious eye irritation.
May cause drowsiness or dizziness.
Suspected of causing genetic defects.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version
6.0

Revision Date:
14.04.2025

SDS Number:
10875044-00011

Date of last issue: 04.02.2025
Date of first issue: 20.10.2022

Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

Hygiene measures	Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
	Take care to prevent spills, waste and minimize release to the environment.
	<ul style="list-style-type: none">If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use.The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers	<ul style="list-style-type: none">Keep in properly labelled containers. Store locked up. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.
Advice on common storage	<ul style="list-style-type: none">Do not store with the following product types:<ul style="list-style-type: none">Strong oxidizing agentsGases

7.3 Specific end use(s)

Specific use(s)	<ul style="list-style-type: none">No data available
-----------------	---

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Propan-2-ol	67-63-0	TWA	100 ppm 245 mg/m ³	FOR-2011-12-06-1358
Ivermectin	70288-86-7	TWA	30 µg/m ³ (OEB 3)	Internal
Further information: Skin				
		Wipe limit	300 µg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-	Workers	Inhalation	Long-term systemic effects	0,18 mg/m ³

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 10875044-00011 Date of last issue: 04.02.2025 Date of first issue: 20.10.2022

carboxylate				
	Workers	Inhalation	Long-term local effects	0,18 mg/m3
	Workers	Skin contact	Long-term systemic effects	0,05 mg/kg bw/day
Cetyl octanoate	Workers	Inhalation	Long-term systemic effects	6,01 mg/m3
	Workers	Inhalation	Acute systemic effects	18,029 mg/m3
	Workers	Skin contact	Long-term systemic effects	17,043 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	51,128 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	1,483 mg/m3
	Consumers	Inhalation	Acute systemic effects	4,448 mg/m3
	Consumers	Skin contact	Long-term systemic effects	8,52 mg/kg bw/day
	Consumers	Skin contact	Acute systemic effects	25,56 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0,851 mg/kg bw/day
	Consumers	Ingestion	Acute systemic effects	2,554 mg/kg bw/day
Propan-2-ol	Workers	Inhalation	Long-term systemic effects	500 mg/m3
	Workers	Skin contact	Long-term systemic effects	888 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	89 mg/m3
	Consumers	Skin contact	Long-term systemic effects	319 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	26 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate	Fresh water	0,024 mg/l
	Freshwater - intermittent	0,24 mg/l
	Marine water	0,0024 mg/l
	Sewage treatment plant	19,5 mg/l
	Fresh water sediment	0,211 mg/kg dry weight (d.w.)
	Marine sediment	0,0211 mg/kg dry weight (d.w.)
	Soil	0,0282 mg/kg dry weight (d.w.)
Propan-2-ol	Fresh water	140,9 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 10875044-00011 Date of last issue: 04.02.2025 Date of first issue: 20.10.2022

	Marine water	140,9 mg/l
	Intermittent use/release	140,9 mg/l
	Sewage treatment plant	2251 mg/l
	Fresh water sediment	552 mg/kg dry weight (d.w.)
	Marine sediment	552 mg/kg dry weight (d.w.)
	Soil	28 mg/kg dry weight (d.w.)
	Oral (Secondary Poisoning)	160 mg/kg food
Ivermectin	Fresh water	0,000004 mg/l
	Marine water	0,000004 mg/l

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter should conform to NS EN 14387
Filter type	: Organic vapour type (A)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : liquid

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 10875044-00011 Date of last issue: 04.02.2025
Date of first issue: 20.10.2022

Colour : clear
Straw-coloured

Odour : characteristic

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity
Viscosity, kinematic : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

Particle size : Not applicable

9.2 Other information

Explosives	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Evaporation rate	: No data available
Molecular weight	: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

|| Not classified based on available information.

Product:

Acute oral toxicity	: Acute toxicity estimate: > 2.000 mg/kg Method: Calculation method
Acute dermal toxicity	: Acute toxicity estimate: > 2.000 mg/kg Method: Calculation method

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

Components:

Propan-2-ol:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 25 mg/l
Exposure time: 6 h
Test atmosphere: vapour
Acute dermal toxicity : LD50 (Rabbit): > 5.000 mg/kg

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Acute oral toxicity : LD50 (Rat, male): > 2.959 - 5.000 mg/kg
Method: OECD Test Guideline 401
Acute inhalation toxicity : LC50 (Rat): >= 5,19 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 436
Assessment: The substance or mixture has no acute inhalation toxicity
Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.
Acute inhalation toxicity : LC50 (Rat): 5,11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist
Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

Skin corrosion/irritation

|| Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 10875044-00011 Date of last issue: 04.02.2025
Date of first issue: 20.10.2022

Components:

Propan-2-ol:

Species : Rabbit
Result : No skin irritation

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Ivermectin:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

||| Causes serious eye irritation.

Components:

Propan-2-ol:

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species : Rabbit
Method : OECD Test Guideline 405
Result : No eye irritation

Ivermectin:

Species : Rabbit
Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

||| May cause an allergic skin reaction.

Respiratory sensitisation

||| Not classified based on available information.

Components:

Propan-2-ol:

Test Type : Buehler Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 10875044-00011 Date of last issue: 04.02.2025
Date of first issue: 20.10.2022

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : positive

Assessment : Probability or evidence of skin sensitisation in humans

Ivermectin:

Exposure routes : Dermal
Species : Humans
Result : Does not cause skin sensitisation.

Germ cell mutagenicity

II Suspected of causing genetic defects.

Components:

Propan-2-ol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: positive

Test Type: In vitro mammalian cell gene mutation test
Result: positive

Test Type: In vitro sister chromatid exchange assay in mammalian cells
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: positive

Genotoxicity in vivo : Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo
Species: Rat
Application Route: Ingestion

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

Method: OECD Test Guideline 486
Result: negative

Test Type: Micronucleus test
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Test Type: Transgenic rodent somatic cell gene mutation assay
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 488
Result: positive

Germ cell mutagenicity- Assessment : Positive result(s) from in vivo mammalian somatic cell mutagenicity tests.

Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts
Result: negative

Test Type: Mouse Lymphoma
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Propan-2-ol:

Species : Rat
Application Route : inhalation (vapour)
Exposure time : 104 weeks
Method : OECD Test Guideline 451
Result : negative

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species : Mouse
Application Route : Skin contact
Exposure time : 29 Months
Result : negative

Ivermectin:

Species : Rat

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

Application Route	:	Oral
NOAEL	:	1,5 mg/kg body weight
Result	:	negative
Remarks	:	Based on data from similar materials
Species	:	Mouse
Application Route	:	Oral
NOAEL	:	2,0 mg/kg body weight
Result	:	negative
Remarks	:	Based on data from similar materials

Reproductive toxicity

||| Not classified based on available information.

Components:

Propan-2-ol:

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Method: OECD Test Guideline 414 Result: negative
-------------------------------	---	---

Ivermectin:

Effects on fertility	:	Test Type: Fertility Species: Rat Application Route: Oral Fertility: NOAEL: 0,6 mg/kg body weight Result: Animal testing did not show any effects on fertility.
Effects on foetal development	:	Test Type: Development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 0,2 mg/kg body weight Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses
		Test Type: Development Species: Rat

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

Application Route: Oral
Developmental Toxicity: LOAEL: 0,4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

STOT - single exposure

|| May cause drowsiness or dizziness.

Components:

Propan-2-ol:

Assessment : May cause drowsiness or dizziness.

Ivermectin:

Target Organs : Central nervous system
Assessment : Causes damage to organs.

STOT - repeated exposure

|| Not classified based on available information.

Components:

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Exposure routes : Ingestion
Target Organs : nasal cavity
Assessment : Shown to produce significant health effects in animals at concentrations of >10 to 100 mg/kg bw.

Ivermectin:

Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Propan-2-ol:

Species : Rat
NOAEL : 12,5 mg/l
Application Route : inhalation (vapour)
Exposure time : 104 Weeks

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 10875044-00011 Date of last issue: 04.02.2025
Date of first issue: 20.10.2022

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Species : Rat
NOAEL : 5 mg/kg
LOAEL : 50 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Method : OECD Test Guideline 408

Ivermectin:

Species : Dog
NOAEL : 0,5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system
Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1,2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 0,4 mg/kg
LOAEL : 0,8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : spleen, Bone marrow, Kidney

Aspiration toxicity

|| Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

|| Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Ivermectin:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

Skin contact	: Remarks: Can be absorbed through skin.
Eye contact	: Remarks: May irritate eyes.
Ingestion	: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

SECTION 12: Ecological information

12.1 Toxicity

Components:

Propan-2-ol:

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): 9.640 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 10.000 mg/l Exposure time: 24 h
Toxicity to microorganisms	: EC50 (Pseudomonas putida): > 1.050 mg/l Exposure time: 16 h

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 24 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 40 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 110 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (Raphidocelis subcapitata (freshwater green alga)): 30 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

Toxicity to microorganisms

Toxicity to microorganisms	: EC10 (activated sludge): 409 mg/l Exposure time: 3 h Method: OECD Test Guideline 209
----------------------------	--

Ivermectin:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 0,003 mg/l Exposure time: 96 h
	LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,0048 mg/l Exposure time: 96 h

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0,000025 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 9,1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 9,1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	:	10.000
M-Factor (Chronic aquatic toxicity)	:	10.000

12.2 Persistence and degradability

Components:

Propan-2-ol:

Biodegradability	:	Result: rapidly degradable
BOD/COD	:	BOD: 1,19 (BOD5) COD: 2,23 BOD/COD: 53 %

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 71 % Exposure time: 28 d Method: OECD Test Guideline 301B
------------------	---	---

Ivermectin:

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 240 d
------------------	---	--

12.3 Bioaccumulative potential

Components:

Propan-2-ol:

Partition coefficient: n-octanol/water	:	log Pow: 0,05
--	---	---------------

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Partition coefficient: n-octanol/water	:	log Pow: 1,34 Method: OECD Test Guideline 107
--	---	--

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74
Partition coefficient: n-octanol/water : log Pow: 3,22

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3082
ADR : UN 3082

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0 Revision Date: 14.04.2025 SDS Number: 10875044-00011 Date of last issue: 04.02.2025
Date of first issue: 20.10.2022

RID : UN 3082

IMDG : UN 3082

IATA : UN 3082

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Ivermectin)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Ivermectin)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Ivermectin)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Ivermectin)

IATA : Environmentally hazardous substance, liquid, n.o.s.
(Ivermectin)

14.3 Transport hazard class(es)

	Class	Subsidiary risks
ADN	: 9	
ADR	: 9	
RID	: 9	
IMDG	: 9	
IATA	: 9	

14.4 Packing group

ADN

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

IMDG

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passenger aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered: Number on list 3

REACH - Restrictions on the manufacture, placing on

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version
6.0

Revision Date:
14.04.2025

SDS Number:
10875044-00011

Date of last issue: 04.02.2025
Date of first issue: 20.10.2022

the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).

: Not applicable

REACH - List of substances subject to authorisation (Annex XIV)

: Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer

: Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast)

: Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals

: Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

	Quantity 1	Quantity 2
E1	100 t	200 t

ENVIRONMENTAL HAZARDS

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version 6.0	Revision Date: 14.04.2025	SDS Number: 10875044-00011	Date of last issue: 04.02.2025 Date of first issue: 20.10.2022
----------------	------------------------------	-------------------------------	---

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H225	: Highly flammable liquid and vapour.
H300	: Fatal if swallowed.
H311	: Toxic in contact with skin.
H317	: May cause an allergic skin reaction.
H319	: Causes serious eye irritation.
H336	: May cause drowsiness or dizziness.
H341	: Suspected of causing genetic defects.
H370	: Causes damage to organs if swallowed.
H372	: Causes damage to organs through prolonged or repeated exposure if swallowed.
H373	: May cause damage to organs through prolonged or repeated exposure.
H400	: Very toxic to aquatic life.
H410	: Very toxic to aquatic life with long lasting effects.
H412	: Harmful to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox.	: Acute toxicity
Aquatic Acute	: Short-term (acute) aquatic hazard
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Eye Irrit.	: Eye irritation
Flam. Liq.	: Flammable liquids
Muta.	: Germ cell mutagenicity
Skin Sens.	: Skin sensitisation
STOT RE	: Specific target organ toxicity - repeated exposure
STOT SE	: Specific target organ toxicity - single exposure
FOR-2011-12-06-1358	: Norway. Occupational Exposure limits
FOR-2011-12-06-1358 /	: Long term exposure limit
TWA	

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - Interna-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ivermectin (0.50%) Liquid Formulation

Version
6.0

Revision Date:
14.04.2025

SDS Number:
10875044-00011

Date of last issue: 04.02.2025
Date of first issue: 20.10.2022

tional Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Eye Irrit. 2	H319
Skin Sens. 1	H317
Muta. 2	H341
STOT SE 3	H336
Aquatic Acute 1	H400
Aquatic Chronic 1	H410

Classification procedure:

Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN